This paper is a broad evidence review of human pharmacokinetic studies on THC and CBD. It helps clarify how route, formulation, food, sex, drug interactions, and patient factors can meaningfully change absorption and exposure. Its main limitation is that it synthesizes heterogeneous studies rather than providing one unified, practice-ready dosing framework.
What Does the Evidence Really Say About Cannabis Risks and Medical Benefits?
Chronic patterns of cannabis use have been associated with multiple adverse outcomes that are of particular concern among adolescents and young adults, such as disrupted learning, impaired cognitive performance, reduced educational attainment and an increased risk of CUD, psychosis/schizophrenia, mood and anxiety disorders and suicidal behaviors.
Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.
The global burden of chronic health conditions is significant. Medicinal cannabis (MC) is a legalised treatment option for patients with chronic health condi…
The 4 Dimensions of Rising Marijuana Positivity Rates in Workplace Drug Tests
Introduction Marijuana Positivity Rates in workplace drug tests have soared to a 25-year high, sparking a diverse range of views and approaches to cannabis use by employees. Let's delve into four distinct...
Cannabinoids vs. Opioids: Exploration and Evolution of Pain Management
Discover the potential of cannabinoids in pain management. Explore medical insights, opposition viewpoints, and real experiences. Learn how cannabinoids could reshape the future of pain treatment. Introduction: The opioid crisis has become...